Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

Y0001516

Rivastigmine hydrogen tartrate

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

Rivastigmine tartrate, ENA-713, Ethylmethyl-carbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester, N-Ethyl-N-methyl-carbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester tartrate, S-Rivastigmine tartrate

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C14H22N2O2 · C4H6O6
Numéro CAS:
129101-54-8
Poids moléculaire :
400.42
Code UNSPSC :
41116107
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

rivastigmine

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

InChI

1S/C14H22N2O2.C4H6O6/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4;5-1(3(7)8)2(6)4(9)10/h7-11H,6H2,1-5H3;1-2,5-6H,(H,7,8)(H,9,10)/t11-;1-,2-/m00/s1

Clé InChI

GWHQHAUAXRMMOT-RWALOXMOSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Rivastigmine hydrogen tartrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

Rivastigmine is an orally available, brain penetrant, reversible cholinesterase inhibitor that enhances cognitive function in patients with Alzheimer′s and Parkinson′s diseases. Rivastigmine inhibits both butyrylcholinesterase and acetylcholinesterase.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Y0001485

Rivastigmine for system suitability, European Pharmacopoeia (EP) Reference Standard

Y0001515

Rivastigmine impurity D, European Pharmacopoeia (EP) Reference Standard

1604811

Rivastigmine Related Compound C, United States Pharmacopeia (USP) Reference Standard

1604836

Rivastigmine, United States Pharmacopeia (USP) Reference Standard

1604825

Rivastigmine Related Compound D, United States Pharmacopeia (USP) Reference Standard

1604847

Rivastigmine tartrate R-isomer, United States Pharmacopeia (USP) Reference Standard

1604869

Rivastigmine Related Compound A, United States Pharmacopeia (USP) Reference Standard

1604858

Rivastigmine tartrate, United States Pharmacopeia (USP) Reference Standard

1604870

Rivastigmine Related Compound B, United States Pharmacopeia (USP) Reference Standard

1604961

Rivastigmine Related Compound F, United States Pharmacopeia (USP) Reference Standard

1604950

Rivastigmine Related Compound E, United States Pharmacopeia (USP) Reference Standard

PHR2034

Rivastigmine Related Compound F, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2032

Rivastigmine Related Compound D, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2031

Rivastigmine Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2029

Rivastigmine Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2033

Rivastigmine Related Compound E, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2030

Rivastigmine Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

Pictogrammes

Skull and crossbonesEnvironment
GHS06,GHS09

Mention d'avertissement

Danger

Mentions de danger

H300,H411

Classification des risques

Acute Tox. 2 Oral - Aquatic Chronic 2

Code de la classe de stockage

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Nastaran Majdi Nasab et al.
JPMA. The Journal of the Pakistan Medical Association, 62(7), 677-680 (2013-07-23)
To assess the efficacy of the Ginkgo biloba in patients with dementia of the Alzheimer type in slowing down the disease's degenerative progression and the patients' cognitive impairment compared with rivastigmine. Total 56 patients aged 50-75 years, suffering from dementia
Carina Wattmo et al.
Clinical interventions in aging, 8, 329-339 (2013-05-18)
To investigate the long-term effects of cholinesterase inhibitor (ChEI) therapy and the influence of sociodemographic and clinical factors on the use of community-based home help services (HHS) by patients with Alzheimer's disease (AD). This 3-year, prospective, multicenter study included 880
Kevin R Peters
Journal of the American Geriatrics Society, 61(7), 1170-1174 (2013-05-29)
To highlight the utility of using an effect size analysis to communicate the effectiveness of treatment interventions. Secondary analysis. Previously published systematic review on cholinesterase inhibitors (ChEIs) in Alzheimer's disease. Individuals with mild to moderate Alzheimer's disease. Six-month randomized controlled
Katherine L Possin et al.
Movement disorders : official journal of the Movement Disorder Society, 28(10), 1384-1390 (2013-07-13)
The objective of this study was to investigate how acetylcholinesterase inhibitor (ChEI) treatment affects brain function in Parkinson's disease (PD). Twelve patients with PD and either dementia or mild cognitive impairment underwent task-free functional magnetic resonance imaging before and after
Jacqueline Birks et al.
The Cochrane database of systematic reviews, 5(5), CD004744-CD004744 (2013-06-04)
Vascular dementia represents the second most common type of dementia after Alzheimer's disease. In older patients, in particular, the combination of vascular dementia and Alzheimer's disease is common, and is referred to as mixed dementia. The classification of vascular dementia
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique